The Japanese pharmaceutical industry, a vital component of global innovation, faces a talent gap that resonates across multinational corporations. While Japan possesses a wealth of highly skilled professionals, a notable communication disparity impedes recruitment and career advancement, particularly in global…
HOME > REGULATORY
REGULATORY
- Interest Shown in Development of 3 Unapproved Drugs/Indications Including Metyrosine
July 6, 2012
- PMDA to Use Science Committee to Help Strengthen Review System: Executive Director Utsumi
July 5, 2012
- MHLW Approves 2 APIs Including Switch OTC Version of Allegra
July 5, 2012
- New Bar Code Labeling Rules to Take Effect for Oral, Topical Drugs from July 2015
July 3, 2012
- 18 Ethical APIs/35 Products Reported at PAC
July 3, 2012
- MHLW Approves 15 Products Including Inlyta and Tenelia
July 2, 2012
- Mandatory Generic Drug Use Still Impractical Due to People’s Lingering Distrust: MHLW
July 2, 2012
- MHLW Calls for Caution to Secondary Damage from Fainting After HPV Vaccination
June 29, 2012
- MHLW Proposes 2-Stage Discussions on Cost-Effective Assessment of Medical Technologies
June 29, 2012
- JPO Rules Actonel Patent Invalid; Ajinomoto Considering Appeal
June 29, 2012
- MHLW Talks to Drug Makers with Facilities Eligible for Exemption from Planned Power Outages
June 27, 2012
- Targets for Generic Drug Use Should Be Included in Medical Expenditure Optimization Plan: Mr Konishi of DPJ
June 26, 2012
- MHLW Orders Updates from Chugai Following Criticism for Reporting Deficiencies by Roche in US
June 26, 2012
- MHLW Approves 11 Products Including Additional Indication for Lyrica
June 26, 2012
- Median Review Time Down by About Half Since FY2007: PMDA
June 25, 2012
- Antipyretic/Analgesics Are Most Common Cause for Relief Benefits for Damage from ADRs: PMDA
June 25, 2012
- PMDA Adopts New Rule for Staff Re-Employment Effective This Month, No Uses Made Yet
June 25, 2012
- 166 Applications Received for Preliminary Interviews for Regulatory Strategy Consultation in First 9 Months: PMDA
June 25, 2012
- Claims of “Ineffective” Generics Might Be Due to Placebo Effect in Some Cases: Mr Yoshida of HIB
June 25, 2012
- MHLW to Strengthen Focus on Dementia with Budget Request for FY2013
June 22, 2012
ページ
Following the launch of two new therapies since last year, Japan has seen fresh moves in drug development for amyotrophic…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…